05:49:24 EDT Mon 15 Aug 2022
Enter Symbol
or Name

Login ID:
Avicanna Inc
Symbol AVCN
Shares Issued 45,858,596
Close 2021-12-23 C$ 0.86
Recent Sedar Documents

Avicanna completes first export of CBG to EU

2021-12-24 07:51 ET - News Release

An anonymous director reports


Through its majority-owned Colombian subsidiary, Santa Marta Golden Hemp SAS (SMGH), Avicanna Inc. has expanded reach for its Aureus raw materials in the European Union with a commercial export of purified cannabigerol (CBG) into the Czech Republic.

The completed export into the Czech Republic marks the company's first commercial export of CBG into the European Union and the 12th market that the Aureus branded products have entered. The new market entrance further demonstrates the company's rapidly expanding international business model and validates the company's leadership in innovation and the commercialization of rare cannabinoids. Aureus branded CBG is cultivated through organic certified and sustainable practices at Avicanna's Santa Marta Golden Hemp (SMGH) facilities. The CBG is also extracted and purified through Avicanna's proprietary processes to provide an isolated and purified form.

To the knowledge of the company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

About cannabigerol (CBG)

CBG has strong anti-inflammatory properties, making it an exciting potential option for formulating topical treatments for arthritis, and muscle and joint pain, as well as prospective oral treatments to address gut inflammation on a cellular level. CBG is considered a rare and non-psychoactive cannabinoid that acts as the precursor to other more commonly known cannabinoids including CBD (cannabidiol) and THC (tetrahydrocannabinol). CBG is typically expressed in low amounts in common cultivars of cannabis; however, Avicanna has propagated proprietary cultivars that express exceptionally high amounts of the rare cannabinoid. CBG has been shown to have anti-inflammatory, anti-bacterial and neuroprotective properties. CBG also has the potential to be formulated across various delivery forms including topical and ingestible for a given therapeutic focus.

About Avicanna Inc.

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.